Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of JR-171 in MPS I
NCT04453085Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- May 2025
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of lepunafusp alfa in mucopolysaccharidosis type I, sponsored by JCR Pharmaceuticals. Started Oct 2021; status: completed.
02
Drugs
lepunafusp alfa
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT04453085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453085.